Currently, there are 1.47B common shares owned by the public and among those 1.46B shares have been available to trade.
The company’s stock has a 5-day price change of 2.36% and 21.98% over the past three months. BSX shares are trading 18.65% year to date (YTD), with the 12-month market performance up to 63.00% higher. It has a 12-month low price of $64.54 and touched a high of $107.17 over the same period. BSX has an average intraday trading volume of 5.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.86%, 11.28%, and 26.55% respectively.
Institutional ownership of Boston Scientific Corp (NYSE: BSX) shares accounts for 91.53% of the company’s 1.47B shares outstanding.
It has a market capitalization of $156.20B and a beta (3y monthly) value of 0.78. The stock’s trailing 12-month PE ratio is 84.94, while the earnings-per-share (ttm) stands at $1.25. The company has a PEG of 6.31 and a Quick Ratio of 1.02 with the debt-to-equity ratio at 0.54. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.83% over the week and 1.65% over the month.
Earnings per share for the fiscal year are expected to increase by 13.91%, and 14.05% over the next financial year. EPS should grow at an annualized rate of 13.47% over the next five years, compared to -17.81% over the past 5-year period.
Looking at the support for the BSX, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on January 10, 2025, with the firm’s price target at $108. Goldman was of a view on May 30, 2024 that the stock is Buy, while Mizuho gave the stock Buy rating on February 01, 2024, issuing a price target of $65- $80. Robert W. Baird on their part issued Outperform rating on July 19, 2023.
